Clinical Trial Update: Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function [NA]

View source ↗

Summary

This document describes a clinical research trial comparing two doses of alteplase (1.0 mg vs 2.0 mg) to restore function of hemodialysis catheters.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Alteplase (Activase) (alteplase)

Snippet

Sponsor: University of Windsor | Conditions: Kidney Disease | NA | Status: UNKNOWN